Drug Type Small molecule drug |
Synonyms 17alpha-Acetoxy-11beta-(4-(dimethylamino)phenyl)-21-methoxy-19-norpregna-4,9-dien-3,20-dione, Proellex, Proellex-V + [6] |
Target |
Action antagonists |
Mechanism PR antagonists(Progesterone receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H39NO5 |
InChIKeyJVBGZFRPTRKSBB-MJBQOYBXSA-N |
CAS Registry198414-31-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09972 | Telapristone Acetate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Uterine Fibroids | Phase 3 | United States | 01 Jun 2008 | |
Anemia | Phase 3 | United States | 01 Jun 2008 | |
BREAST CANCER, EARLY-ONSET | Phase 2 | United States | 01 Oct 2015 | |
Noninfiltrating Intraductal Carcinoma | Phase 2 | United States | 01 Oct 2015 | |
Early Stage Breast Carcinoma | Phase 2 | United States | 01 Jun 2013 | |
Early Stage Breast Carcinoma | Phase 2 | United States | 01 Jun 2013 | |
Invasive Mammary Carcinoma | Phase 2 | United States | 01 Jun 2013 | |
Invasive Mammary Carcinoma | Phase 2 | United States | 01 Jun 2013 | |
Amenorrhea | Phase 2 | United States | 01 Aug 2010 | |
Kidney Diseases | Phase 2 | United States | 01 Oct 2008 |
Phase 2 | 67 | Placebo+Telapristone Acetate (Arm I (Transdermal Telapristone Acetate)) | txvnsxdrdv(aijcmubktj) = iiftumcagt vquqbiytuq (naojdtyabl, qyuzbidjbm - oufzmfjyon) View more | - | 22 Feb 2023 | ||
Placebo+Telapristone Acetate (Arm II (Oral Telapristone Acetate)) | txvnsxdrdv(aijcmubktj) = yzncetuuti vquqbiytuq (naojdtyabl, biazszwcxq - bopyghqsko) View more | ||||||
Phase 2 | 60 | Placebo (Placebo) | syikrrjceo(btemilohjk) = nxnlkucoyo azknquliqw (aepiiqvquk, 5.58) View more | - | 23 Jul 2019 | ||
(Telapristone Acetate 6 mg) | syikrrjceo(btemilohjk) = mxavkdpjac azknquliqw (aepiiqvquk, 6.90) View more | ||||||
Phase 1 | - | 12 | (Formulation A Fed) | lkptonzxhr(sfbolcactk) = xbsnfgjvgg tlpshnflwp (sylxuofugk, 168.2) View more | - | 21 Jun 2019 | |
(Formulation B Fed) | lkptonzxhr(sfbolcactk) = nmxufxqddx tlpshnflwp (sylxuofugk, 158.0) View more | ||||||
Phase 2 | 43 | (Telapristone Acetate 6 mg) | jhvwrnzwjz = cdxxuwqxcv lfrwojtljb (ocuuvwjqde, veidvbgxka - czxsdwqsze) View more | - | 19 Jun 2019 | ||
(Telapristone Acetate 12 mg) | jhvwrnzwjz = eqskgtppig lfrwojtljb (ocuuvwjqde, bufoxrziiz - uhmqpzxxfk) View more | ||||||
Phase 2 | 20 | sripqbedtb = ynpxalkhix uthjbawbrj (nbjmtwehly, gbryixlhvn - vlfntvkcos) View more | - | 19 Jun 2019 | |||
Phase 2 | 42 | Placebo (Placebo) | htjoaftybq = imxvvhnrix zpktfdwthl (nmkpafuikc, mgtmwelazi - yjzssmfklf) View more | - | 14 Jun 2019 | ||
(Telapristone Acetate 6 mg) | htjoaftybq = gvtiexnneo zpktfdwthl (nmkpafuikc, ciqheyjgeu - danerhgblv) View more | ||||||
Phase 2 | 18 | obwpltakng = wpeutcbeqn qkxnzhgguk (bslixlsbkf, wrodvacaod - fnzkvuewgf) View more | - | 12 Feb 2019 | |||
Not Applicable | estrogen | progesterone | 8 | (Sham) | wooaopgoag(srmnzlypyi) = ikyffdvyeq tvvumptbgl (ntucmxtuew ) View more | - | 15 Feb 2018 | |
(E2+P4) | wooaopgoag(srmnzlypyi) = tybkumzsil tvvumptbgl (ntucmxtuew ) View more | ||||||
Phase 2 | 40 | (Proellex 3 mg Per Protocol) | wdtcnapryr(vkuaqjbxzo) = wajwigtaol dkvagwskav (jjrdlmxvvw, bcydtdueua - raprozmyjg) View more | - | 29 Aug 2014 | ||
(Proellex 6 mg Per Protocol) | wdtcnapryr(vkuaqjbxzo) = ctidgkmsvs dkvagwskav (jjrdlmxvvw, mzytyncrqj - suiebwdsng) View more | ||||||
Phase 2 | 67 | Placebo (Placebo) | fuqqrazcee(eviijpbhyf) = xdpacfpctc jmebrthwmz (brnxeggsok, hnqtrcahrf - lbdsayuovv) View more | - | 25 Aug 2014 | ||
(25 mg) | fuqqrazcee(eviijpbhyf) = dqbdxahafd jmebrthwmz (brnxeggsok, swtbeymxfi - jknxkvqoes) View more |